Monday, August 20, 2007

ISIS Pharmaceuticals, Inc. (Public, NASDAQ:ISIS)

It looks like the shorts are in trouble here!

Isis Pharmaceuticals, Inc. is a biopharmaceutical company exploiting ribonucleic acid (RNA)-based drug discovery technologies to create a class of drugs to treat important diseases. The Company, with its primary technology, antisense, creates inhibitors, called oligonucleotides, designed to hybridize, with a high degree of specificity to their RNA target and modulate the production of specific proteins associated with disease. Separately, within the Company’s Ibis Biosciences, Inc. subsidiary, Isis Pharmaceuticals, Inc. has developed a biosensor system, called the Ibis T5000 Biosensor System, which can simultaneously identify from a sample a range of infectious organisms without needing to know beforehand what might be present in the sample. The Company is commercializing the Ibis T5000 Biosensor System for use in biodefense, forensics, epidemiological surveillance, infectious disease research, hospital-associated infection control.